Next Article in Journal
Human Papilloma Virus Inoculation: Why Only Girls?
Previous Article in Journal
Might Positron Emission Tomography Actually Treat Micrometastatic Cancer?
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Optimal Use of Taxanes in Metastatic Breast Cancer

Department of Medical Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada
Tom Baker Cancer Centre, Calgary, AB, Canada
Alberta International Medical Graduate Program, University of Calgary, Calgary, AB, Canada
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(3), 8-20;
Submission received: 2 January 2009 / Revised: 4 March 2009 / Accepted: 3 April 2009 / Published: 1 May 2009


The role of taxanes in the treatment of breast cancer is becoming increasingly important. In clinical practice, the taxanes are now standard therapy in both early-stage and metastatic breast cancer. Since the 1990s, multiple randomized clinical trials have been evaluating the efficacy of taxanes in the treatment of metastatic breast cancer. These trials have included treatment with taxanes alone or in combination with other chemotherapeutic agents. Pre-existing published guidelines for the use of taxanes in the management of metastatic breast cancer are available. The mandate of the Alberta Cancer Board Provincial Breast Tumour Group Guideline Panel was to consider and adapt the recommendations of the existing guidelines and to develop de novo guidelines to account for current evidence. For this task, the panel used the adapte process, which is a systematic process of guideline adaptation developed by the adapte Collaboration. The recommendations formulated by the panel included the identification of taxane regimens that could be offered in anthracycline-naïve patients, anthracycline-pretreated or -resistant patients, and patients overexpressing the human epidermal growth factor receptor 2. Potential toxicities and benefits in terms of time to progression, progression-free survival, overall survival, and quality of life were also considered.
Keywords: metastatic breast cancer; docetaxel; paclitaxel; nab-paclitaxel; chemotherapy metastatic breast cancer; docetaxel; paclitaxel; nab-paclitaxel; chemotherapy

Share and Cite

MDPI and ACS Style

King, K.M.; Lupichuk, S.; Baig, L.; Webster, M.; Basi, S.; Whyte, D.; Rix, S. Optimal Use of Taxanes in Metastatic Breast Cancer. Curr. Oncol. 2009, 16, 8-20.

AMA Style

King KM, Lupichuk S, Baig L, Webster M, Basi S, Whyte D, Rix S. Optimal Use of Taxanes in Metastatic Breast Cancer. Current Oncology. 2009; 16(3):8-20.

Chicago/Turabian Style

King, Karen M., S. Lupichuk, L. Baig, M. Webster, S. Basi, D. Whyte, and S. Rix. 2009. "Optimal Use of Taxanes in Metastatic Breast Cancer" Current Oncology 16, no. 3: 8-20.

Article Metrics

Back to TopTop